title: [The role of neurotropic therapy in the treatment of acute sensorineural impairment of hearing following a viral infection].
abstract: The objective of the study. To estimate the efficacy of consecutive prescription of combined neurotropic therapy in addition to conventional treatment modalities for the patients presenting with acute sensorineural impairment of hearing. The results of analysis of the examination and treatment of 58 patients presenting with acute sensorineural impairment of hearing following a viral infection are presented. The patients of the study group (group 1) received the treatment according to the following scheme: intramuscular injections of milgamma at a dose of 2 ml for 10 days followed by the intake of milgamma tablets thrice daily during 20 days. The control patients (group 2) was comprised of the patients given conventional therapy alone. The efficacy of the treatment was estimated based on the results of tonal threshold audiometry before and after the treatment. It was shown that neurotropic therapy can speed up the process of hearing recovery in the patients suffering its acute sensorineural impairment by at least 5 days. The efficacy of traditional treatment combined with milgamma therapy in the patients with acute sensorineural impairment of hearing of allegedly viral etiology proved to be higher than that of conventional therapy alone within the first days after the onset of the treatment.
authors.forename: A G
authors.initials: AG
authors.lastname: Atanesian
authors.forename: S Ia
authors.initials: SIa
authors.lastname: Kosiakov
mesh_terms: D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D001682:Biological Availability; D003056:Cochlear Nerve / Q000187:drug effects* / Q000503:physiopathology; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D007758:Ear, Inner / Q000294:innervation; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006320:Hearing Tests / Q000379:methods*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents; D013831:Thiamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D014777:Virus Diseases / Q000150:complications*
chemical_list: D000276:Adjuvants, Immunologic; D018696:Neuroprotective Agents; D013831:Thiamine; C013835:benphothiamine